SIETES :: 93212 citas

Resultados de la búsqueda por PUBLICACIONES REFINAR BÚSQUEDA

1.

Ward BJ, Makarkov A, Séguin A, Pillet S, Trépanier S, Dhaliwall J, Libman MD, Vesikari T, Landry N. Efficacy, immunogenicity, and safety of a plant-derived, quadrivalent, virus-like particle influenza vaccine in adults (18–64 years) and older adults (=65 years): two multicentre, randomised phase 3 trials. Lancet 2020;396:13 de octubre. [Ref.ID 103743]

2.

Novoa A. Ni formación ni investigación: relaciones públicas, propaganda y corrupción. NoGracias 2020:2 de agosto. [Ref.ID 103695]

3.

Moynihan R, MacDonald H, Bero L, Godlee F. Commercial influence and covid-19. BMJ 2020;369:24 de junio. [Ref.ID 103680]

4.

Samper E. Así afectan las prisas a la ciencia que rodea al coronavirus . eldiario.es 2020:23 de junio. [Ref.ID 103667]

5.

Borraz M, Ferrer S. Historia de un escándalo: una empresa sospechosa y el estudio que sacudió a la prestigiosa revista 'The Lancet' . eldiario.es 2020:6 de junio. [Ref.ID 103642]

6.

Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular disease, drug therapy, and mortality in covid-19. N Engl J Med 2020;382:18 de junio. [Ref.ID 103602]

7.

Dal-Ré R, Kesselheim AS, Bourgeois FT. Increasing access to FDA inspection reports on irregularities and misconduct in clinical trials. JAMA 2020:23 de abril. [Ref.ID 103599]

8.

Di Maio M, Audisio M, Cardone C, De Luca E, Gargiulo P, Zichi C, Perrone F. The use of not-negative conclusions to describe results of formally negative trials presented at oncology meetings. JAMA Oncology 2020:1. [Ref.ID 103598]

9.

Koblan KS, Kent J, Hopkins SC, Krystal JH, Cheng H, Goldman R, Loebel A. A non–D2-receptor-binding drug for the treatment of schizophrenia. N Engl J Med 2020;382:1497-506. [Ref.ID 103592]

10.

DeVito NJ, Bacon S, Goldacre B. Compliance with legal requirement to report clinical trial results on ClinicalTrials.gov: a cohort study. Lancet 2020;395:1 de febrero. [Ref.ID 103519]

11.

Anónimo. Visual Abstracts . N Engl J Med 2019:. [Ref.ID 103228]

12.

Tatsioni A, Karassa FB, Goodman SN, Zarin DA, Fanelli D, Ioannidis JPA. Lost evidence from registered large long-unpublished randomized controlled trials: a survey. Ann Intern Med 2019:7 de mayo. [Ref.ID 103117]

13.

Khan MS, Lateef N, Siddiqi TJ, Rehmab KA, Alnaimat S, Khan SU, Riaz H, Murad H, Mandrola J, Doukky R, Krasuski RA. Level and prevalence of spin in published cardiovascular randomized clinical trial reports with statistically nonsignificant primary outcomes. A systematic review. JAMA Network Open 2019:3 de mayo. [Ref.ID 103114]

14.

Agarwal A, Ioannidis JPA. PREDIMED trial of Mediterranean diet: retracted, republished, still trusted?. BMJ 2019;364:7 de febrero. [Ref.ID 103032]

15.

Healy D. The Goetzsche affair. Dr. David Healy (blog) 2018:5 de noviembre. [Ref.ID 102892]

16.

King MA. Pregabalin and gabapentin associated with depression and suicidal ideation. BMJ 2018;363:29 de noviembre. [Ref.ID 102862]

17.

Bafeta A, Koh M, Riveros C, Ravaud P. Harms reporting in randomized controlled trials of interventions aimed at modifying microbiota: a systematic review. Ann Intern Med 2018;169:240-7. [Ref.ID 102815]

18.

Kitchlu A, Shapiro J, Amir E, Garg AX, Kim J, Wald R, Harel Z. Representation of patients with chronic kidney disease in trials of cancer therapy. JAMA 2018;319:19 de junio. [Ref.ID 102790]

19.

Anónimo. Cannabinoids: just like any other medication?. Lancet 2018;392:21 de julio. [Ref.ID 102744]

20.

Garattini S, Bertele V. Benefits, benefits, once more benefits... with no risk? Stop overlooking the harms of medicines. Eur J Clin Pharmacol 2018;74:marzo. [Ref.ID 102550]